Patrick C Wilson

List of Publications by Year
in descending order

104 papers	11,801 citations	41627 51 h-index	42259 96 g-index
137 all docs	137 docs citations	137 times ranked	14812 citing authors

#	Article	IF	Citations
1	Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model. Journal of Virology, 2022, 96, JVI0142121.	1.5	11
2	Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature, 2022, 602, 314-320.	13.7	78
3	Teach â€˜em young: Influenza vaccines induce broadly neutralizing antibodies in children. Cell Reports Medicine, 2022, 3, 100531.	3.3	1
4	Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens. Briefings in Bioinformatics, 2022, 23, .	3.2	2
5	Memory B cell diversity: insights for optimized vaccine design. Trends in Immunology, 2022, 43, 343-354.	2.9	12
6	Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies. Journal of Virology, 2022, , e0033222.	1.5	8
7	Proinflammatory IgG Fc structures in patients with severe COVID-19. Nature Immunology, 2021, 22, 67-73.	7.0	239
8	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine, 2021, 27, 106-114.	15.2	204
9	SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. MBio, 2021, 12, .	1.8	81
10	Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model. MBio, 2021, 12, .	1.8	19
11	Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
12	Extrafollicular CD4 T cell-derived IL-10 functions rapidly and transiently to support anti-Plasmodium humoral immunity. PLoS Pathogens, 2021, 17, e1009288.	2.1	13
13	Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase. MSphere, 2021, 6, .	1.3	15
14	Hemolysis-associated phosphatidylserine exposure promotes polyclonal plasmablast differentiation. Journal of Experimental Medicine, 2021, 218, .	4.2	12
15	B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Viruses, 2021, 13, 965.	1.5	31
16	An Egg-Derived Sulfated<i>N</i>-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. MBio, 2021, 12, e0083821.	1.8	8
17	First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Science Translational Medicine, 2021, 13, .	5.8	38
18	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity, 2021, 54, 1290-1303.e7.	6.6	101

#	Article	IF	Citations
19	Bridging the B Cell Gap: Novel Technologies to Study Antigen-Specific Human B Cell Responses. Vaccines, 2021, 9, 711.	2.1	4
20	Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus. Nature Communications, 2021, 12, 6161.	5.8	6
21	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. MBio, 2021, 12, e0297521.	1.8	24
22	Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohnâ€™s disease. Nature Microbiology, 2021, 6, 1493-1504.	5.9	77
23	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infectious Diseases, The, 2020, 20, 80-91.	4.6	103
24	Aging and influenza vaccine-induced immunity. Cellular Immunology, 2020, 348, 103998.	1.4	87
25	Itâ€™s Hard to Teach an Old B Cell New Tricks. Cell, 2020, 180, 18-20.	13.5	4
26	Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice. Vaccine, 2020, 38, 7129-7137.	1.7	23
27	Imprinting, immunodominance, and other impediments to generating broad influenza immunity. Immunological Reviews, 2020, 296, 191-204.	2.8	42
28	Machine Learning to Quantify In Situ Humoral Selection in Human Lupus Tubulointerstitial Inflammation. Frontiers in Immunology, 2020, 11, 593177.	2.2	4
29	Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Immunity, 2020, 53, 1230-1244.e5.	6.6	61
30	Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity. Journal of Virology, 2020, 94, .	1.5	3
31	Remembering seasonal coronaviruses. Science, 2020, 370, 1272-1273.	6.0	32
32	Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Science Translational Medicine, 2020, 12, .	5.8	77
33	Characterizing Emerging Canine H3 Influenza Viruses. PLoS Pathogens, 2020, 16, e1008409.	2.1	29
34	High-complexity extracellular barcoding using a viral hemagglutinin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2767-2769.	3.3	2
35	Biochemical patterns of antibody polyreactivity revealed through a bioinformatics-based analysis of CDR loops. ELife, 2020, 9, .	2.8	29
36	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0

#	ARTICLE	IF	CITATIONS
37	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
38	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
39	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
40	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
41	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
42	The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain. Nature Microbiology, 2019, 4, 2216-2225.	5.9	59
43	Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study. Journal of Virology, 2019, 93, .	1.5	18
44	Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell, 2019, 178, 1313-1328.e13.	13.5	402
45	Nur77 Links Chronic Antigen Stimulation to B Cell Tolerance by Restricting the Survival of Self-Reactive B Cells in the Periphery. Journal of Immunology, 2019, 202, 2907-2923.	0.4	29
46	Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. Cell Host and Microbe, 2019, 25, 357-366.e6.	5.1	124
47	Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans. Cell Reports, 2019, 29, 4460-4470.e8.	2.9	22
48	Emerging from the Shadow of Hemagglutinin: Neuraminidase Is an Important Target for Influenza Vaccination. Cell Host and Microbe, 2019, 26, 712-713.	5.1	13
49	Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance. Journal of Virology, 2019, 93, .	1.5	47
50	An Efficient Method to Generate Monoclonal Antibodies from Human B Cells. Methods in Molecular Biology, 2019, 1904, 109-145.	0.4	43
51	Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin. ELife, 2019, 8, .	2.8	80
52	Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. Cell, 2018, 173, 417-429.e10.	13.5	295
53	NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?. MBio, 2018, 9, .	1.8	192
54	What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028803.	2.3	11

#	Article	IF	Citations
55	From Original Antigenic Sin to the Universal Influenza Virus Vaccine. Trends in Immunology, 2018, 39, 70-79.	2.9	208
56	Editorial overview: Tough targets. Current Opinion in Immunology, 2018, 53, iv-vi.	2.4	0
57	Characterization of the immunologic repertoire: A quick start guide. Immunological Reviews, 2018, 284, 5-8.	2.8	0
58	The influenza virus hemagglutinin head evolves faster than the stalk domain. Scientific Reports, 2018, 8, 10432.	1.6	171
59	Crowd on a Chip: Label-Free Human Monoclonal Antibody Arrays for Serotyping Influenza. Analytical Chemistry, 2018, 90, 9583-9590.	3.2	19
60	Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge. Journal of Virology, 2018, 92, .	1.5	33
61	Harnessing immune history to combat influenza viruses. Current Opinion in Immunology, 2018, 53, 187-195.	2.4	64
62	Spec-seq unveils transcriptional subpopulations of antibody-secreting cells following influenza vaccination. Journal of Clinical Investigation, 2018, 129, 93-105.	3.9	40
63	BASIC: BCR assembly from single cells. Bioinformatics, 2017, 33, 425-427.	1.8	87
64	Single-Cell Genomics: Approaches and Utility in Immunology. Trends in Immunology, 2017, 38, 140-149.	2.9	66
65	Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation. Science Immunology, 2017, 2, .	5.6	203
66	Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nature Communications, 2017, 8, 846.	5.8	134
67	Natural polyreactive IgA antibodies coat the intestinal microbiota. Science, 2017, 358, .	6.0	344
68	Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo. Scientific Reports, 2017, 7, 10857.	1.6	29
69	Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies. Journal of Visualized Experiments, 2017, , .	0.2	8
70	Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12578-12583.	3.3	437
71	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. PLoS Pathogens, 2016, 12, e1005815.	2.1	104
72	B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts. Journal of Virology, 2016, 90, 5574-5585.	1.5	111

#	Article	IF	Citations
73	To B or not to B maintained?. Blood, 2016, 128, 317-318.	0.6	3
74	Refined protocol for generating monoclonal antibodies from single human and murine B cells. Journal of Immunological Methods, 2016, 438, 67-70.	0.6	65
75	Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11931-11936.	3.3	153
76	Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nature Medicine, 2016, 22, 1456-1464.	15.2	271
77	Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host and Microbe, 2016, 19, 800-813.	5.1	238
78	Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?. Current Opinion in Immunology, 2016, 42, 48-55.	2.4	78
79	Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7852-7857.	3.3	479
80	Taking the Broad View on B Cell Affinity Maturation. Immunity, 2016, 44, 518-520.	6.6	7
81	Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. Journal of Clinical Investigation, 2016, 126, 605-610.	3.9	349
82	High Preexisting Serological Antibody Levels Correlate with Diversification of the Influenza Vaccine Response. Journal of Virology, 2015, 89, 3308-3317.	1.5	112
83	Germinal Center Selection and the Antibody Response to Influenza. Cell, 2015, 163, 545-548.	13.5	83
84	Restricted, canonical, stereotyped and convergent immunoglobulin responses. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140238.	1.8	75
85	Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. Immunity, 2015, 43, 541-553.	6.6	425
86	Immune history profoundly affects broadly protective B cell responses to influenza. Science Translational Medicine, 2015, 7, 316ra192.	5.8	353
87	Loss of Anergic B Cells in Prediabetic and New-Onset Type 1 Diabetic Patients. Diabetes, 2015, 64, 1703-1712.	0.3	79
88	Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. Journal of Clinical Investigation, 2015, 125, 1255-1268.	3.9	115
89	High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. PLoS ONE, 2015, 10, e0125618.	1.1	35
90	Biogenesis of Influenza A Virus Hemagglutinin Cross-Protective Stem Epitopes. PLoS Pathogens, 2014, 10, e1004204.	2.1	8

#	Article	IF	Citations
91	Vimentin Is a Dominant Target of In Situ Humoral Immunity in Human Lupus Tubulointerstitial Nephritis. Arthritis and Rheumatology, 2014, 66, 3359-3370.	2.9	82
92	Restricted VH/VL usage and limited mutations in gluten-specific IgA of coeliac disease lesion plasma cells. Nature Communications, 2014, 5, 4041.	5.8	46
93	Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013â€"2014 influenza season. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15798-15803.	3.3	203
94	<i>Staphylococcus aureus</i> infection induces protein Aâ€"mediated immune evasion in humans. Journal of Experimental Medicine, 2014, 211, 2331-2339.	4.2	125
95	Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13133-13138.	3.3	197
96	Crossâ€reactive humoral responses to influenza and their implications for a universal vaccine. Annals of the New York Academy of Sciences, 2013, 1283, 13-21.	1.8	38
97	Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9047-9052.	3.3	371
98	Tools to therapeutically harness the human antibody response. Nature Reviews Immunology, 2012, 12, 709-719.	10.6	128
99	Immunodominance of Antigenic Site B over Site A of Hemagglutinin of Recent H3N2 Influenza Viruses. PLoS ONE, 2012, 7, e41895.	1.1	92
100	Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Journal of Experimental Medicine, 2011, 208, 181-193.	4.2	775
101	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 2010, 467, 591-595.	13.7	393
102	Rapid Generation of Rotavirus-Specific Human Monoclonal Antibodies from Small-Intestinal Mucosa. Journal of Immunology, 2010, 185, 5377-5383.	0.4	83
103	Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nature Protocols, 2009, 4, 372-384.	5.5	458
104	Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 2008, 453, 667-671.	13.7	959